Cintredekin besudotox

Recombinant Fusion Toxin (IL 13 Linked To Pseudomonas Exotoxin)Rx: InvestigationalCompound: Investigational

Also known as: Cintredekin, cintredekin besudotox, IL13-PE38QQR

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Cintredekin besudotox at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Cintredekin besudotox is an investigational recombinant fusion protein comprising interleukin‑13 and a truncated Pseudomonas exotoxin (PE38). It is administered by convection‑enhanced intracerebral infusion to target IL‑13Rα2‑expressing glioblastoma.

Mechanism of Action

Binds IL-13Rα2 on tumor cells, internalizes, and the exotoxin domain ADP‑ribosylates EF‑2 halting protein synthesis and inducing cell death

Routes of Administration

Intracerebral Infusion (convection‑enhanced Delivery)

Goals & Uses

  • Treatment of recurrent glioblastomaOncologyModerate

Contraindications

  • Known hypersensitivity to Pseudomonas exotoxinAllergyHigh

Adverse Effects

  • HeadacheNeurologicCommonPain in the head or upper neck
  • Intracranial hemorrhageNeurologicalUncommon
  • Cerebral edemaNeurologicalCommon

Drug Interactions

  • CorticosteroidsLow

Population Constraints

  • Pediatric patientsAgeRelative

Regulatory Status

  • European UnionInvestigationalClinical trial status; no marketing authorization
  • United StatesInvestigationalInvestigational New Drug (IND) application; not FDA‑approved

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is Cintredekin besudotox?

Cintredekin besudotox is an investigational recombinant fusion protein comprising interleukin‑13 and a truncated Pseudomonas exotoxin (PE38). It is administered by convection‑enhanced intracerebral infusion to target IL‑13Rα2‑expressing glioblastoma.

What is Cintredekin besudotox used for?

Cintredekin besudotox is educationally associated with: Treatment of recurrent glioblastoma. Educational only — not medical advice.

How is Cintredekin besudotox administered?

Recorded routes of administration: Intracerebral Infusion (convection‑enhanced Delivery).

What are the potential side effects of Cintredekin besudotox?

Reported adverse effects include: Headache, Intracranial hemorrhage, Cerebral edema. This list is not exhaustive — consult a qualified clinician.

Who should avoid Cintredekin besudotox?

Recorded contraindications: Known hypersensitivity to Pseudomonas exotoxin. Consult a qualified clinician before use.